Patents Examined by Lakia Jackson-Tongue
-
Patent number: 9943584Abstract: Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the present application are also provided.Type: GrantFiled: September 17, 2009Date of Patent: April 17, 2018Assignee: HUNTER IMMUNOLOGY LIMITEDInventors: Margaret Lorraine Dunkley, Robert Llewellyn Clancy
-
Patent number: 9901604Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: February 5, 2016Date of Patent: February 27, 2018Assignee: Crestovo Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 9879268Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.Type: GrantFiled: March 4, 2016Date of Patent: January 30, 2018Assignees: Vakzine Projekt Management GmbH, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Christine Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
-
Patent number: 9878028Abstract: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.Type: GrantFiled: February 18, 2016Date of Patent: January 30, 2018Assignee: Sanofi Pasteur SAInventors: Pierre Chouvenc, Alain Francon
-
Patent number: 9867858Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: February 5, 2016Date of Patent: January 16, 2018Assignee: Crestovo Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 9822167Abstract: The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.Type: GrantFiled: June 16, 2009Date of Patent: November 21, 2017Assignee: Nestec S.A.Inventors: Jalil Benyacoub, Blaise Corthesy, Stephanie Blum-Sperisen, Laurent Favre
-
Patent number: 9789176Abstract: This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.Type: GrantFiled: March 16, 2012Date of Patent: October 17, 2017Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Marnie L. Peterson
-
Patent number: 9789140Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: September 9, 2016Date of Patent: October 17, 2017Assignee: Crestovo Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 9790257Abstract: A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.Type: GrantFiled: January 28, 2016Date of Patent: October 17, 2017Assignee: Scandinavian Biopharma Holding ABInventors: Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
-
Patent number: 9782467Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: GrantFiled: January 20, 2009Date of Patent: October 10, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Paolo Costantino
-
Patent number: 9782466Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: GrantFiled: January 20, 2009Date of Patent: October 10, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Paolo Constantino
-
Patent number: 9737574Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: February 5, 2016Date of Patent: August 22, 2017Assignee: Crestovo LLCInventor: Thomas Julius Borody